ArticleAmerican journal of translational research2026
Antimicrobial effects of compound Huangbai liquid on
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to systematically evaluate the antimicrobial potential of Compound Huangbai Liquid (HB) against
methodsA multidimensional research strategy combining clinical trials, bacteriological experiments and animal model studies was used. The clinical efficacy and adverse effects of HB were observed in patients with abdominal abscesses and non-lactating breast abscesses. The antimicrobial activity of HB was assessed in vitro by minimal inhibitory concentration (MIC), and its antibacterial, anti-inflammatory as well as pro-healing mechanisms were explored in a mouse infection model.
resultsClinical studies of abdominal abscesses showed that patients in the HB treatment group had a significantly lower rate of pus bacterial positivity, lower serum white blood cell (WBC), neutrophil (NEU) and C-reactive protein (CRP) levels, higher levels of vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) and basic fibroblast growth factor (βFGF), reduced pus volume and shorter hospitalization time. Clinical studies of non-lactating breast abscesses showed that HB significantly reduced tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) levels, promoted wound healing and relieved pain. No significant adverse effects were observed in either clinical study, and there was no statistically significant difference in the recurrence rate during long-term follow-up, indicating that HB has a favorable safety profile and stable efficacy. The results of bacteriological experiments showed that the MICs of HB on
conclusionHB possesses antimicrobial effects against
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.